文献速递免疫规划

四价流感血凝素疫苗在印度尼西亚儿童中的免疫原性与安全性:一项开放标签桥接临床研究

Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
PubMed 文献 · Vaccine · 2019-12-17

该开放标签、单臂桥接临床研究纳入6-35月龄(I组)和3-8岁(II组)未免疫健康儿童,两组均接种两剂四价流感血凝素疫苗(间隔28天)。结果显示所有疫苗株血清保护率≥85%,两组均出现>4倍血清转化,无疫苗相关严重不良事件或死亡,研究者认为该疫苗在6月龄至8岁儿童中具有免疫原性和可接受的安全性。

要点

  • 两组儿童接种两剂四价流感血凝素疫苗后,所有疫苗株血清保护率均≥85%。
  • I组A/H1N1、A/H3N2、B/Texas、B/Phuket的GMT分别增长12.5、14.5、8.2、6.4倍。
  • 未报告疫苗相关严重不良事件或死亡。

核心结论

  • 研究中的四价流感血凝素疫苗在6月龄至8岁儿童中具有免疫原性,安全性可接受。

研究设计与样本

  • 开放标签、单臂桥接临床研究,纳入未免疫健康儿童6-35月龄(I组)和3-8岁(II组)。
  • 两组均接种两剂四价流感血凝素疫苗,间隔28天。
  • 基线及接种后28天进行血凝抑制抗体检测,分析GMT、血清保护率和血清转化率。
  • 观察接种后28天内的征集性反应、非征集性不良事件和严重不良事件。

主要发现

  • 270名受试者入组,269名完成研究,254名纳入免疫原性分析。
  • 两组所有疫苗株血清保护率均≥85%。
  • 两组接种后所有疫苗株均出现>4倍血清转化。
  • I组A/H1N1、A/H3N2、B/Texas、B/Phuket的GMT分别增长12.5、14.5、8.2、6.4倍;II组分别增长14、17、10、8倍。
  • 首次和第二次免疫后局部不良事件以即刻注射部位疼痛为主(10.4%和12.6%),全身不良事件以迟发性非征集性不良事件为主(14.8%和14.9%)。

关键数值与推荐

  • 血清保护率:两组所有疫苗株均≥85%。
  • 血清转化:两组所有疫苗株均>4倍。
  • I组GMT增长倍数:A/H1N1 12.5倍、A/H3N2 14.5倍、B/Texas 8.2倍、B/Phuket 6.4倍。
  • II组GMT增长倍数:A/H1N1 14倍、A/H3N2 17倍、B/Texas 10倍、B/Phuket 8倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza B (Yamagata/Victoria lineage) can cause severe forms of respiratory infection among the pediatric population as well as influenza A strains (H3N2/H1N1). Vaccination against all four strains is required to prevent infection and severe outcome. This study is the first study to assess the immunogenicity of Quadrivalent Influenza HA vaccine (QIV) and ascertain safety among children in Indonesia. METHODS: This is an open labeled, single arm, bridging clinical study involving unprimed healthy children 6-35 months of age (Group I) and 3-8 years of age (Group II). Subjects on both groups receiving two doses of QIV with a 28 days interval. Serology tests were performed on baseline and 28 days post-vaccination. Hemagglutination inhibition antibody titers were analyzed for Geometric Mean Titer (GMT), seroprotection, and seroconversion rates. Solicited reactions, unsolicited adverse events, and serious adverse events were observed up to 28 days post-vaccination. RESULTS: Out of 270 subjects enrolled, 269 subjects completed the study. Immunogenicity analysis were evaluated on 254 subjects. Seroprotection rates were ≥85% for all vaccine strains in both groups. Seroconversion of more than 4 folds for all strains occurred in both groups post-vaccination. In Group I, the increase of GMT for A/H1N1, A/H3N2, B/Texas, and B/Phuket was 12.5, 14.5, 8.2, and 6.4 folds, respectively. In Group II the increase of GMT for A/H1N1, A/H3N2, B/Texas, and B/Phuket was 14, 17, 10, and 8 folds, respectively. The majority of local adverse events (AEs) after the first and second immunizations were immediate injection-site pain (10.4% and 12.6%). The majority of systemic AEs after the first and second immunizations were delayed unsolicited AEs (14.8% and 14.9%). No vaccine-related serious adverse events or deaths were reported. CONCLUSION: The investigational QIV was immunogenic with an acceptable safety profile in children 6 months to 8 years of age. CLINICAL TRIAL REGISTRATION: NCT03336593.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dhamayanti M, Tarigan R, Fadlyana E, et al. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study. Vaccine. 2019. PMID: 31862195. doi:10.1016/j.vaccine.2019.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。